{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.4"},{"groupId":"OG001","value":"98.6"}]}],"title":"Any TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.3"},{"groupId":"OG001","value":"90.3"}]}],"title":"Any study drug-related TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.4"},{"groupId":"OG001","value":"34.7"}]}],"title":"Treatment-emergent serious adverse events (TESAEs)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"72"}],"units":"Participants"}],"description":"TEAEs were defined as all AEs starting or worsening within the treatment period.","groups":[{"description":"Test drug: 6.5 mg/kg every 3 weeks; Intravenous (IV) infusion over 1 hour","id":"OG000","title":"Anetumab Ravtansine"},{"description":"Active comparator: 30 mg/m\\^2 once weekly","id":"OG001","title":"Vinorelbine"}],"paramType":"NUMBER","populationDescription":"The secondary efficacy analysis (TEAEs) was performed in the safety analysis set (SAF).","reportingStatus":"POSTED","timeFrame":"Up to approx. 55 months (data cut-off: 02-Jul-2019) - Time from randomization until 30 days after last treatment (general AEs), or further until death from any cause (selected AEs).","title":"Percentage of Participant With Treatment-emergent Adverse Events (TEAEs)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}